替莫唑胺联合大分割放疗治疗弥漫性内生性脑桥胶质瘤:一项随机对照试验
这项II期开放标签随机试验纳入新诊断弥漫性内生性脑桥胶质瘤患者,比较常规分割放疗(60 Gy/30次/6周)与大分割放疗(39 Gy/13次/2.6周)联合同期及辅助替莫唑胺的疗效。共35例随机、33例可评估,两组中位总生存期无显著差异(常规组11个月 vs 试验组12个月,p=0.208),试验组3-4级血液学毒性发生率为28%(n=5)。作者结论为大分割放疗联合同期及辅助替莫唑胺未改善总生存期且血液学毒性更高,常规放疗仍是标准治疗。
要点
- 常规组93%(n=14)完成治疗,试验组仅17%(n=3)完成计划疗程。
- 中位总生存期常规组11个月(95%CI 7.5-14.5)vs 试验组12个月(95%CI 10.5-13.5),p=0.208。
- 试验组28%(n=5)出现3或4级血液学毒性。
核心结论
- 大分割放疗联合同期及辅助替莫唑胺未改善弥漫性内生性脑桥胶质瘤患者的总生存期,且血液学毒性更高;常规放疗仍是标准治疗。
研究设计与样本
- II期开放标签随机试验,纳入新诊断弥漫性内生性脑桥胶质瘤患者,共35例随机,33例可评估,采用改良意向性治疗分析。
主要发现
- 常规组93%(n=14)完成治疗,试验组仅17%(n=3)完成计划疗程。
- 中位总生存期常规组11个月(95%CI 7.5-14.5个月)vs 试验组12个月(95%CI 10.5-13.5个月),p=0.208。
- 试验组28%(n=5)出现3或4级血液学毒性。
关键数值与推荐
- 常规组(A组)接受60 Gy分30次、6周完成的分割放疗。
- 试验组(B组)接受39 Gy分13次、2.6周完成的大分割放疗,同期替莫唑胺75 mg/m2从第1天至第17天,随后辅助替莫唑胺六个周期。
临床怎么用
- 常规放疗仍是弥漫性内生性脑桥胶质瘤的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is the most common form of brainstem glioma. The present study was performed to assess if hypofractionated radiotherapy completed in < 3 weeks with temozolomide improves survival in DIPG. MATERIAL AND METHODS: The present study is a phase II open label randomized trial. The study included newly diagnosed patients with DIPG. Patients in arm A received conventional fractionated RT of 60 Gy in 30 fractions over 6 weeks while patients in arm B received hypo-fractionated radiotherapy of 39 Gy in 13 fractions over 2.6 weeks along with concurrent Temozolomide (TMZ) 75 mg/m2 from day 1 to day 17 followed by adjuvant TMZ for six cycles. The survival analysis was performed with modified intention to treat analysis. RESULTS: A total of 35 patients were randomized. 33 patients were evaluable. 93% (n = 14) of patients in the conventional arm completed treatment while only 17% (n = 3) of the children could complete planned course of treatment in the experimental arm. The median overall survival (OS) was 11 months (95% CI - 7.5 to 14.5 months) in the conventional arm and 12 months (95% CI - 10.5 to 13.5 months) in the experimental arm (p = 0.208). 28% (n = 5) patients in the experimental arm developed grade 3 or 4 hematological toxicity. CONCLUSION: The above study shows that hypofractionated radiotherapy with concurrent and adjuvant temozolomide does not improve OS and has higher hematological toxicity. Conventional radiotherapy remains the standard of care.
引用
- Izzuddeen Y, Gupta S, Haresh KP, et al. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial. J Neurooncol. 2019. PMID: 31728883. doi:10.1007/s11060-019-03340-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。